<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953524</url>
  </required_header>
  <id_info>
    <org_study_id>FUF14</org_study_id>
    <secondary_id>UTN: U1111-1111-4798</secondary_id>
    <nct_id>NCT00953524</nct_id>
  </id_info>
  <brief_title>A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly</brief_title>
  <official_title>Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic
      vaccine.

      Primary Objectives:

        -  To describe the immunogenicity of the candidate vaccines after each injection.

        -  To describe the safety of the candidate vaccines after each injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive two injections of their randomized vaccine on Day 0 and Day 21,
      respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</measure>
    <time_frame>Pre-vaccination (Day 0) and day 21 post-vaccination</time_frame>
    <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</measure>
    <time_frame>Pre-vaccination (Day 0) and Day 21 post-vaccination</time_frame>
    <description>Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</measure>
    <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
    <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1) Strain - Age ≥ 65 Years</measure>
    <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
    <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years</measure>
    <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
    <description>Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years</measure>
    <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
    <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age 18 to 64 Years</measure>
    <time_frame>Days 0 to 7 post-vaccination</time_frame>
    <description>Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age ≥ 65 Years</measure>
    <time_frame>Days 0 to 7 post-vaccination</time_frame>
    <description>Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">849</enrollment>
  <condition>Influenza</condition>
  <condition>Swine-origin A/H1N1 Influenza</condition>
  <arm_group>
    <arm_group_label>A/H1N1 Vaccine Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive A/H1N1 vaccine formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/H1N1 Vaccine Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive A/H1N1 vaccine formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/H1N1 Vaccine Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive A/H1N1 Vaccine formulation 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0 and on Day 21</description>
    <arm_group_label>A/H1N1 Vaccine Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0 and Day 21</description>
    <arm_group_label>A/H1N1 Vaccine Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0 and day 21</description>
    <arm_group_label>A/H1N1 Vaccine Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal saline solution (placebo)</intervention_name>
    <description>0.5 mL, Intramuscular on Day 0 and Day 21</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Healthy adults aged 18 years or older on the day of inclusion

          -  Informed consent has been signed and dated

          -  Able to attend all scheduled visits and comply with all trial procedures

          -  For a woman of child-bearing potential, use of an effective method of contraception or
             abstinence from at least 4 weeks prior to the first vaccination, until at least 4
             weeks after last vaccination.

        Exclusion Criteria :

          -  Known pregnancy or positive urine pregnancy test

          -  Currently breastfeeding a child

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination

          -  Planned receipt of any vaccine prior to the Day 42 blood sample

          -  Receipt of blood or blood-derived products in the past 3 months which might interfere
             with the assessment of immune response

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2
             consecutive weeks within the past 3 months)

          -  Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B
             antigen, or Hepatitis C

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine(s) used in the trial or to a vaccine
             containing any of the same substances

          -  Self reported thrombocytopenia contraindicating intramuscular (IM) vaccination

          -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion
             contraindicating IM vaccination

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Current alcohol abuse or drug addiction that may interfere with the subject's ability
             to comply with trial procedures

          -  Chronic illness that in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Employees of the Investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that Investigator or study center, as
             well as family members of the employees or the Investigator.

          -  Previous participation in a swine-origin H1N1 pandemic flu trial except if performed
             in 1976

          -  Any confirmed case of influenza (including swine-origin A/H1N1 Influenza) since March
             2009

          -  Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C]) or moderate or severe acute
             illness/infection (according to Investigator judgment) on the day of vaccination

          -  Personal or family history of Guillain-Barré syndrome

          -  Active neoplastic disease or a history of any hematologic malignancy

          -  Known seizure/epilepsy history and/or taking anti-seizure medication

          -  Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and
             stable for at least 3 months prior to enrollment, without decompensating symptoms will
             be allowed to enroll in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maddisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010 Jan 2;375(9708):41-8. doi: 10.1016/S0140-6736(09)62026-2. Epub 2009 Dec 15.</citation>
    <PMID>20018365</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>June 8, 2011</results_first_submitted>
  <results_first_submitted_qc>June 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2011</results_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Pandemic Flu</keyword>
  <keyword>Swine-origin A/H1N1 Influenza</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 06 August 2009 to 07 August 2009 at 15 US clinical centers.</recruitment_details>
      <pre_assignment_details>A total of 849 participants who met the inclusion and exclusion criteria were enrolled, vaccinated, and included in data analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A/H1N1 Vaccine Group 1</title>
          <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="P2">
          <title>A/H1N1 Vaccine Group 2</title>
          <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="P3">
          <title>A/H1N1 Vaccine Group 3</title>
          <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Group</title>
          <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="254"/>
                <participants group_id="P3" count="247"/>
                <participants group_id="P4" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="239"/>
                <participants group_id="P3" count="233"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A/H1N1 Vaccine Group 1</title>
          <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="B2">
          <title>A/H1N1 Vaccine Group 2</title>
          <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="B3">
          <title>A/H1N1 Vaccine Group 3</title>
          <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Group</title>
          <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="254"/>
            <count group_id="B3" value="247"/>
            <count group_id="B4" value="99"/>
            <count group_id="B5" value="849"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="19.2"/>
                    <measurement group_id="B2" value="53.4" spread="18.9"/>
                    <measurement group_id="B3" value="54.4" spread="18.4"/>
                    <measurement group_id="B4" value="56.4" spread="18.1"/>
                    <measurement group_id="B5" value="53.4" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="247"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</title>
        <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
        <time_frame>Pre-vaccination (Day 0) and day 21 post-vaccination</time_frame>
        <population>Pre- and post-vaccination antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</title>
          <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
          <population>Pre- and post-vaccination antibody titers were assessed in the per-protocol population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination 1 (Day 0) Titers at ≥ 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 1 (Day 21) Titers at ≥ 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 2 (Day 42) Titers at ≥ 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</title>
        <description>Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
        <time_frame>Pre-vaccination (Day 0) and Day 21 post-vaccination</time_frame>
        <population>Antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</title>
          <description>Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
          <population>Antibody titers were assessed in the per-protocol population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination 1 (Day 0) Titers at ≥ 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 1 (Day 21) Titers at ≥ 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 2 (Day 42) Titers at ≥ 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</title>
        <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
        <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
        <population>Antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years</title>
          <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
          <population>Antibody titers were assessed in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination 1 (Day 0) GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="11.6" upper_limit="18.1"/>
                    <measurement group_id="O2" value="17.3" lower_limit="13.5" upper_limit="22.1"/>
                    <measurement group_id="O3" value="14.1" lower_limit="11.0" upper_limit="18.0"/>
                    <measurement group_id="O4" value="14.0" lower_limit="9.31" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 1 (Day 21) GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="708" lower_limit="555" upper_limit="903"/>
                    <measurement group_id="O2" value="1362" lower_limit="1073" upper_limit="1729"/>
                    <measurement group_id="O3" value="1526" lower_limit="1229" upper_limit="1895"/>
                    <measurement group_id="O4" value="13.1" lower_limit="8.89" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 2 (Day 42) GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800" lower_limit="650" upper_limit="986"/>
                    <measurement group_id="O2" value="1329" lower_limit="1059" upper_limit="1669"/>
                    <measurement group_id="O3" value="1331" lower_limit="1082" upper_limit="1638"/>
                    <measurement group_id="O4" value="13.5" lower_limit="9.23" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1) Strain - Age ≥ 65 Years</title>
        <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
        <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
        <population>Pre- and post-vaccination antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1) Strain - Age ≥ 65 Years</title>
          <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
          <population>Pre- and post-vaccination antibody titers were assessed in the per-protocol population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination 1 (Day 0) Titers at ≥ 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 1 (Day 21) Titers at ≥ 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 2 (Day 42) Titers at ≥ 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years</title>
        <description>Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
        <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
        <population>Pre- and post-vaccination antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years</title>
          <description>Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
          <population>Pre- and post-vaccination antibody titers were assessed in the per-protocol population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination 1 (Day 0) Titers at ≥ 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 1 (Day 21) Titers at ≥ 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 2 (Day 42) Titers at ≥ 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years</title>
        <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
        <time_frame>Pre-vaccination (Day 0) and 21 days post-vaccination</time_frame>
        <population>Antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years</title>
          <description>Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.</description>
          <population>Antibody titers were assessed in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination 1 (Day 0) GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="14.8" upper_limit="24.5"/>
                    <measurement group_id="O2" value="14.7" lower_limit="12.0" upper_limit="18.1"/>
                    <measurement group_id="O3" value="18.3" lower_limit="14.1" upper_limit="23.7"/>
                    <measurement group_id="O4" value="17.5" lower_limit="11.0" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 1 (Day 21) GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319" lower_limit="229" upper_limit="443"/>
                    <measurement group_id="O2" value="423" lower_limit="298" upper_limit="600"/>
                    <measurement group_id="O3" value="578" lower_limit="408" upper_limit="819"/>
                    <measurement group_id="O4" value="17.5" lower_limit="11.2" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination 2 (Day 42) GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359" lower_limit="268" upper_limit="481"/>
                    <measurement group_id="O2" value="416" lower_limit="311" upper_limit="556"/>
                    <measurement group_id="O3" value="604" lower_limit="442" upper_limit="827"/>
                    <measurement group_id="O4" value="19.0" lower_limit="12.1" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age 18 to 64 Years</title>
        <description>Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).</description>
        <time_frame>Days 0 to 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age 18 to 64 Years</title>
          <description>Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).</description>
          <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Prevents daily activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 Solicited Systemic Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 102.1 F or ≥ 39.0 C) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Headache (Prevents daily activity), Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Malaise (Prevents daily activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Myalgia (Prevents daily activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (Prevents activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age ≥ 65 Years</title>
        <description>Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).</description>
        <time_frame>Days 0 to 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>A/H1N1 Vaccine Group 1</title>
            <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O2">
            <title>A/H1N1 Vaccine Group 2</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O3">
            <title>A/H1N1 Vaccine Group 3</title>
            <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age ≥ 65 Years</title>
          <description>Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).</description>
          <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Prevents daily activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis (&gt; 10 cm) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 Solicited Systemic Reaction - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 102.1 ºF or ≥ 39.0 ºC) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Headache (Prevents daily activity), Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Malaise (Prevents daily activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Myalgia (Prevents daily activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering - Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering - Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (Prevents activity) - Any Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination to up to 6 months post-vaccination 2.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A/H1N1 Vaccine Group 1</title>
          <description>Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="E2">
          <title>A/H1N1 Vaccine Group 2</title>
          <description>Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="E3">
          <title>A/H1N1 Vaccine Group 3</title>
          <description>Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Group</title>
          <description>Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignan</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Non-Hodgkins lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Global amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="248"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="246"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="246"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="246"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="246"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="246"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

